Chrome 2001
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
. .
Chrome 2001
Chrome 2001
Health News Health News
Long-Acting HIV Drug May Offer Better Protection Against Infection
March 04, 2014


TUESDAY, March 4, 2014 (HealthDay News) -- A long-acting, injectable HIV drug could potentially protect people from infection with the AIDS virus for up to three months, new animal studies suggest.

The experimental drug, called GSK744, protected macaque monkeys from repeated attempts to infect the animals with a hybrid simian/human AIDS virus called SHIV, scientists said.

GSK744 is a reformulated, long-acting version of an HIV drug known as dolutegravir (Tivicay), which has been approved by the U.S. Food and Drug Administration for treatment in people who have already been infected with HIV.

While GSK744 hasn't been tested on humans, doctors hope that it will lead to a medication that could effectively protect people against HIV infection, mostly because it would only need to be administered on a quarterly basis. However, findings from animal studies often don't hold up in human trials.

Such a long-lasting drug would help overcome one of the major problems with current medications that attempt to protect against HIV infection -- the ability of people to take their medication on a daily basis.

"Some of the really good pre-exposure prophylaxis treatments have not been effective, mainly because people don't take the drug," said Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. "The major stumbling block the field has experienced has been the lack of adherence. It's not because the drugs don't work. It's because people don't take them as directed."

Researchers expect to launch human trials for GSK744 within a matter of months, said study author Chasity Andrews, a scientist with the Aaron Diamond AIDS Research Center at Rockefeller University in New York City.

GSK744 is in a class of antiretroviral drugs called integrase inhibitors. These medications block HIV from inserting its genetic material into the body's immune cells.

GSK744 is different in that it crystallizes in the bloodstream, allowing a slow, steady release of the medicine over time, the Rockefeller researchers explained.

Their findings are published online March 6 in the journal Science. The Rockefeller study, and similar results from a study conducted by researchers at the U.S. Centers for Disease Control and Prevention, were presented Tuesday at the annual Conference on Retroviruses and Opportunistic Infections in Boston, according to published reports.

The medication levels that protected the monkeys translate to doses that could sustain human protection for 12 weeks to 16 weeks, Andrews said.

Effective protection against HIV is necessary to fight the spread of AIDS. There were 2.3 million new HIV infections globally in 2012, the researchers noted in background material, with more than 35.3 million people already infected.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on preventing HIV infection.

Copyright © 2014 HealthDay. All rights reserved.

SOURCES: Anthony Fauci, M.D., director, U.S. National Institute of Allergy and Infectious Diseases; Chasity Andrews, researcher, Aaron Diamond AIDS Research Center, Rockefeller University, New York City; March 6, 2014, Science, online...

More News
InteliHealth .
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
    Print Printer-friendly format    
This website is certified by Health On the Net Foundation. Click to verify.